Arrowhead’s Plozasiran Cuts Triglycerides, Pancreatitis Risk in Phase 3 TrialsMarket Beat·1 day ago, 03:02 PMARWR+0.83%
Arrowhead Pharmaceuticals' (ARWR) "Outperform" Rating Reaffirmed at Royal Bank Of CanadaMarket Beat·1 day ago, 01:24 PMARWR+0.83%BLK-2.02%
Arrowhead Pharmaceuticals posts ESC 2026 investor presentation on SHASTA-3 and SHASTA-4 resultsPUBT·1 day ago, 01:18 PMARWR+0.83%
ARWR: Plozasiran showed robust efficacy and safety in Phase 3 sHTG trials, supporting global regulatory filingsQuartr·1 day ago, 07:50 AMARWR+0.83%
Arrowhead Phase 3 SHASTA-3, SHASTA-4 studies met primary endpointsbusinessinsider·1 day ago, 02:50 AMARWR+0.83%
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia | ARWR Stock NewsStockTitan·2 days ago, 07:30 AMARWR+0.83%
Arrowhead Pharma director Michael S. Perry disposes of 11,600 shares for $1.01 millionPUBT·Aug 20 at 09:23 PMARWR+0.83%
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce TriglyceridesMorningStar·Aug 17 at 01:38 PMARWR+0.83%
Arrowhead Pharmaceuticals Earnings Call Signals Confident ExpansionTip Ranks·Aug 16 at 12:29 AMARWR+0.83%
How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening LossesSimplywall·Aug 11 at 03:41 AMARWR+0.83%
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Rating of "Moderate Buy" from BrokeragesMarket Beat·Aug 9 at 06:29 AMARWR+0.83%BLK-2.02%
Arrowhead publishes transcript of fiscal 2026 third-quarter conference callPUBT·Aug 4 at 09:48 PMARWR+0.83%
Arrowhead Pharma acquires FDA rare pediatric disease priority review voucherPUBT·Aug 4 at 08:40 PMARWR+0.83%
California State Teachers Retirement System Has $9.05 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWRMarket Beat·Aug 4 at 07:37 AMARWR+0.83%
